DuPen A, Shen D, Ersek M: Mechanisms of opioid-induced tolerance and hyperalgesia. Pain Manag Nurs 2007, 8 (3) : 113–21. ReviewCrossRefPubMed 4. World Health Organization Guidelines: Cancer Control. Journal of the Moffitt Cancer Center 1999, 6 (2) : 191–197. 5. Quigley C: Opioid switching to improve pain relief and drug tolerability (Cochrane Review). The Cochrane Library Chichester, UK: John Wiley & Sons 2004., (4) : 6. Mercadante S: Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 1999, 86 (9) : 1856–66.CrossRefPubMed 7. Moryl N, Santiago-Palma J, Kornick C, Derby S, Fischberg D, Payne R, GDC-0941 supplier Manfredi PL: Pitfalls of opioid rotation: substituting another opioid for methadone
in patients with cancer pain. Pain 2002, 96 (3) : 325–8.CrossRefPubMed Mizoribine purchase 8. de Stoutz ND, Bruera E, Suarez-Almazor M: Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995, 10 (5) : 378–84.CrossRefPubMed 9. Sittl R, Likar R, Nautrup
BP: Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther 2005, 27 (2) : 225–37.CrossRefPubMed 10. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E: Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing. J Pain Symptom Manage 2001, 22 (2) : 672–87.CrossRefPubMed 11. Williams RL, Chen ML, Hauck WW: Equivalence approaches. 4SC-202 mw Clin Pharmacol Ther 2002, 72 (3) : 229–37.CrossRefPubMed 12. Bruera E, MacMillan K, Hanson J, MacDonald RN: The Edmonton staging system for cancer pain: preliminary report. Pain 1989, 37 (2) : 203–9.CrossRefPubMed Montelukast Sodium 13. Portenoy RK: Tolerance to opioid analgesics: clinical aspects. Cancer Surv 1994, 21: 49–65.PubMed 14. Mercadante S, Bruera E: Opioid switching: a systematic and critical review. Cancer Treat Rev 2006, 32 (4) : 304–15.CrossRefPubMed
15. Donner B, Zenz M, Tryba M, Strumpf M: Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996, 64 (3) : 527–34.CrossRefPubMed 16. Mercadante S, Porzio G, Fulfaro F, Aielli F, Verna L, Ficorella C, Casuccio A, Riina S, Intravaia G, Mangione S: Switching from transdermal drugs: an observational “”N of 1″” study of fentanyl and buprenorphine. J Pain Symptom Manage 2007, 34 (5) : 532–8.CrossRefPubMed 17. Ward S, Donovan H, Gunnarsdottir S, Serlin RC, Shapiro GR, Hughes S: A randomized trial of a representational intervention to decrease cancer pain (RIDcancerPain). Health Psychol 2008, 27 (1) : 59–67.CrossRefPubMed 18. Donovan HS, Ward S, Sherwood P, Serlin RC: Evaluation of the Symptom Representation Questionnaire (SRQ) for Assessing Cancer-Related Symptoms. J Pain Symptom Manage 2008, 35 (3) : 242–57.CrossRefPubMed 19. Ward S, Hughes S, Donovan H, Serlin RC: Patient education in pain control. Support Care Cancer 2001, 9 (3) : 148–55.CrossRefPubMed 20.